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Abstract 
 
The ATP-binding cassette (ABC) superfamily G member 2 (ABCG2) transmembrane 
protein transporter is known for conferring resistance to treatment in cancers. 
Photodynamic therapy (PDT) is a promising anti-cancer method involving the use of 
light-activated photosensitisers to precisely induce oxidative stress and cell death in 
cancers. ABCG2 can efflux photosensitisers from out of cells, reducing the capacity 
of PDT and limiting the efficacy of treatment. Many studies have attempted to 
elucidate the relationship between the expression of ABCG2 in cancers, its effect on 
the cellular retention of photosensitisers and its impact on PDT. This review looks at 
the studies which investigate the effect of ABCG2 on a range of different 
photosensitisers in different pre-clinical models of cancer. This work also evaluates 
the approaches that are being investigated to address the role of ABCG2 in PDT 
with an outlook on potential clinical validation. 
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1 Introduction 
Anti-cancer Photodynamic Therapy (PDT) involves the administration of a tumour-
retaining photosensitiser that is activated by light of a specific wavelength from a 
ground to an excited state of energy. The activated and unstable photosensitiser 
subsequently transfers the additional energy to oxygen to produce reactive oxygen 
species (ROS) [1–3]. Cytotoxic ROS cause tumour destruction through different 
mechanisms including apoptosis, necrosis, destruction of tumour vasculature, 
inflammation and the induction of the innate immune system [4]. The type of tumour 
and cell death elicited depends on the type of photosensitiser used, the type of cell 
and tissue under investigation, the intracellular localisation of the photosensitiser and 
the total dose of light administered [3]. Unlike systemic chemo- and biological 
therapy, PDT is site-specific and light irradiation is localised to the area of tumour 
growth [5,6]. In recent decades, many different types and classes of photosensitisers 
have been investigated including Haematoporphyrin derivatives, Porfimer Sodium 
(Photofrin), Aminolevulinic acid (ALA), meta(tetrahydroxyphenyl)chlorin (mTHPC), 
mono-L-aspartyl chlorin e6 (NPe6) and Hypericin [7]. Clinically, PDT can be applied 
as a standalone method of treatment or in adjunct with surgery or chemotherapy 
[8,9]. 
 
The ATP-binding cassette (ABC) superfamily G member 2 (ABCG2) transporter, also 
known as the breast cancer resistance protein (BCRP), is predominantly located in 
the cell membrane. The primary role of ABCG2 is to actively pump out endogenous 
metabolites, xenobiotics and toxins from cells or into intracellular compartments such 
as the endoplasmic reticulum for elimination [10,11]. In cancer research, ABCG2 has 
long been identified as one of the major contributors to multidrug resistance and 
treatment failure. Chemotherapeutic compounds such as doxorubicin, methotrexate, 
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mitoxantrone and topotecan have been identified as substrates of ABCG2 activity 
[12]. Clinically, high ABCG2 expression correlates with poor prognosis in acute 
myeloid leukaemia patients, as indicated by poor complete response, disease-free 
survival and overall survival [13]. Additionally, key genetic alterations such as the 
R482G ‘gain-of-function’ mutation have been identified in increasing drug efflux 
activity [11,14–17]. 
 
Research into ABCG2 has focused on identifying its role in conferring resistance to 
treatment. Many investigations have been conducted in an effort to reverse drug 
resistance and improve chemosensitivity. This includes the use of structurally-
diverse small molecule inhibitors to bind and antagonise ABCG2 efflux pump activity, 
targeting ABCG2 protein translation through RNA-interfering retrovirus.  This 
modulates intracellular signalling pathways that regulate ABCG2 activity, 
circumventing resistance by using compounds that are poor ABCG2 substrates 
[11,18–21]. 
 
Many studies have been conducted to investigate the interplay between ABCG2, the 
pharmacokinetics of various photosensitisers and the effect they have on the 
efficiency of PDT. Compared to other well-documented multidrug resistant proteins 
such as P-glycoprotein and Multidrug resistance-associated protein 1, ABCG2 has 
been found to have the largest impact on influencing the accumulation of 
photosensitisers and impeding PDT (Figure 1) [22]. All the studies evaluated in this 
review have been summarised in Table 1. This review has been categorised 
according to the different types of photosensitisers and will highlight the key 
developments and findings in understanding the role of ABCG2 in PDT. Studies 
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looking at techniques which attempt to overcome the PDT-limiting effect of ABCG2 
will also be discussed in this review.  
 
2 ABCG2 influences the accumulation of photosensitisers and PDT 
2.1 Pheophorbide-a 
Phephorbide-a (PPa) is a photosensitiser derived from the metabolism and 
breakdown of chlorophyll. PPa possess efficient PDT-mediating properties with 
promising potential clinical application [23]. Jonker et al. conducted the earliest study 
looking at the effect of ABCG2 and intratumoural accumulation of photosensitisers 
[24]. In this in vivo investigation, abcg2-knockdown mice were generated and fed a 
chlorophyll-rich diet using alfalfa leaf concentrate. Under ambient lighting conditions, 
abcg2-knockdown mice were found to be hypersensitive to the diet as characterised 
by epidermal phototoxicity. Plasma levels of PPa were found to be significantly 
higher in these mice when compared to both wild-type mice on the chlorophyll-rich 
diet and abcg2-knockdown mice on a normal diet. The authors confirmed the 
transportation of PPa by ABCG2 by incubating ABCG2-overexpressing MEF3.8 
(murine fibroblast) cells with PPa. An 18-fold reduction in intracellular PPa levels was 
observed in ABCG2-overexpressing cells when compared to parental cells, which 
could be reversed by Ko143 (a small molecule ABCG2 inhibitor). Kim et al. 
investigated the influence of ABCG2 in PPa treated SW480 and HT29 colorectal 
cancer cell lines [25]. PPa uptake and retention was found to be higher in SW480 
cells as compared to HT29, which correlated with the low and high ABCG2 protein 
expression levels respectively. SW480 cells were found to be more sensitive to PPa-
PDT than HT29 cells. To confirm the involvement of ABCG2, Ko143 pre-treated 
HT29 cells, prior to PPa-PDT, were found to be more sensitive to PDT than non-
Ko143 pre-treated cells. ABCG2-overexpressing SW480 cells were found to be more 
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resistant to PPa-PDT than parental cells. Intracellular levels of ROS correlated with 
cell survival, with low levels being detected in resistant cells. In vivo analysis 
confirmed these findings: ABCG2-overexpressing SW480 xenografts were resistant 
to PPa-PDT as characterised by the continuous growth in sizes of xenografts 
following PDT. HT29 xenograft bearing mice treated with Ko143 and PPa-PDT were 
found to have a larger reduction in tumour growth when compared to PPa-PDT only 
treated mice. The overexpression and oncogenic activation of the transmembrane 
tyrosine kinase linked receptor cMET has been linked to the promotion and 
development of tumour growth through the stimulation of various downstream 
signalling pathways, including the cancer-progressing PI3K/Akt pathway [26,27]. 
Increased PI3K/Akt signalling has previously been found to increase the expression 
of ABCG2 [28,29]. Jung et al. found doxorubicin-resistant A2780 ovarian cancer cells 
to be more resistant to PPa-PDT when compared to their non-doxorubicin-resistant 
counterpart [30]. ABCG2 was the only gene among the 50 sampled ABC 
transporters in which expression was elevated more than 50% in the doxorubicin-
resistant A2780 cells via both genetic and protein expression analysis. This study 
found an increase in cMET expression and PI3K/Akt signalling which could have 
contributed to increased ABCG2 expression. The inhibition of PI3K/Akt and 
repression of cMET lead to the suppression of ABCG2 which resulted in increased 
uptake of PPa, increased ROS production and improved responses to PPa-PDT in 
doxorubicin-resistant cells. Ko143 treatment improved sensitivity to PPa-PDT 
doxorubicin-resistant cells. Pan et al. investigated the responses of different human 
glioma cell lines to PDT, mediated by methyl ester pyropheophorbide-a (MPPa) [31]. 
The authors observed significant differences in sensitivity to MPPa-PDT between the 
different glioma cells lines. U251 and A172 cell lines were found to be the least and 
most resistant to treatment respectively. U251 cells had high intracellular 
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accumulation of MPPa and low ABCG2 expression levels. The inverse was found in 
A172 cells. Incubation with the ABCG2 inhibitor fumitremorgin C (FTC) reversed the 
effects of ABCG2 in A172 cells as shown by an increase in MPPa accumulation, 
increased ROS production and overall increased PDT cytotoxicity. In this study, the 
authors highlighted the heterogeneity in ABCG2 expression and varying degrees of 
inherent resistance to PDT between different cell lines of the same type of cancer. In 
comparison, the study by Tao et al. demonstrated acquired resistance in MG63 and 
HOS human osteosarcoma cell lines subjected to multiple cycles of MPPa-PDT and 
establishing PDT resistant cells [32]. Protein expression analysis showed a 
significant increase in ABCG2 expression in resistant cells when compared to 
parental cells. Intracellular accumulation of MPPa and generation of ROS was found 
to be lower in PDT resistant cells. Resistant cells were more capable of invasion, 
migration and colony formation following PDT. Tracy et al. investigated the influence 
of ABCG2 on the photosensitiser 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a 
(HPPa) and subsequent efficacy of PDT in patient-derived primary cultures of lung 
carcinoma, healthy lung epithelial and stromal cells [33]. High ABCG2 expressing 
carcinoma cells were found to eliminate intracellular HPPa when compared to low 
ABCG2 expressing epithelial cells. HPPa was found to be lost from fibroblasts even 
in the absence of ABCG2, suggesting selectivity for epithelial cells. The authors 
confirmed the activity of ABCG2 in a co-culture model comprising of high ABCG2 
expressing carcinoma cells and low ABCG2 expressing tumour fibroblasts in the 
presence and absence of imatinib mesylate (Gleevec, ABCG2 inhibitor). Imatinib 
mesylate was found to prevent the loss of HPPa from carcinoma cells and an 
enhanced retention of HPPa was seen in carcinoma cells over the tumour 
fibroblasts. 
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The transcriptional factor Nrf2 plays a pivotal role in protecting cells against harmful 
stimulants by promoting the expression of cytoprotective genes. Oncogenic 
activation and gain of Nrf2 function can promote tumour survival, protect against 
oxidative stress and confer chemoresistance. Nrf2 has previously been shown to 
induce the upregulation of ABCG2 in cancers as a mechanism of resistance to 
treatment [34,35]. To highlight the interplay between Nrf2 and ABCG2 and its effect 
on PPa-PDT, Choi et al. investigated Nrf2 signalling in PPa treated carcinoma cell 
lines from different cancers [36]. Nrf2-knockdown MDA-MB-231 breast carcinoma 
cells were generated and found to have elevated ROS generation and increased 
intracellular uptake of PPa when compared to control cells. This resulted in 
enhanced cytotoxicity in Nrf2-knockdown cells following PPa-PDT. ABCG2 
expression was found to be significantly reduced in Nrf2-knockdown cells. To 
demonstrate the relationship between Nrf2 and ABCG2, Ko143 treated Nrf2-
knockdown and control cells were found to have no differences in PPa accumulation, 
ROS generation or PPa-PDT cytotoxicity. These findings were further confirmed in 
Nrf2-knockdown and control subtypes of HT29 colorectal carcinoma, MCF7 breast 
carcinoma, HCT116 colorectal carcinoma, A498 renal carcinoma and A172 
glioblastoma cell lines. Tian et al. also investigated the relationship between Nrf2 
signalling, ABCG2 and sensitivity to PDT [37]. An increase in Nrf2 and 
phosphorylated Nrf2 expression was observed in A2780 and SKOV3 human ovarian 
cancer cell lines subjected to MPPa-PDT. siRNA knockdown of Nrf2 improved 
responses to MPPa-PDT as shown by increased cytotoxicity, apoptotic activity and 
increased ROS generation. SKOV3 cells exhibited higher resistance to MPPa-PDT 
and the expression levels of phosphorylated Nrf2 and ABCG2 were found to be 
higher in SKOV3 cells when compared to A2780 cells. This suggests a possible 
interaction between Nrf2 and ABCG2 as a mechanism of resistance to MPPa-PDT. 
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2.2 Aminolevulinic acid/Protoporphyrin IX 
The photosensitiser Protoporphyrin IX (PpIX) is an endogenous metabolite involved 
in the mitochondrial haem biosynthesis pathway. PpIX is a precursor to haem, a vital 
co-factor of haemoglobin that is required for the transportation of oxygen. The 
enzyme ferrochelatase is responsible for the efficient conversion of PpIX to haem. 
PpIX is produced from endogenous ALA under normal physiological conditions; a 
negative feedback loop can detect levels of haem production and inhibit the 
synthesis of ALA. This in turn prevents the accumulation of excess PpIX which can 
lead to phototoxicity. Exogenously administered ALA, can overcome the negative 
feedback mechanism and increase the production of PpIX in cells [38,39]. PpIX is 
known for its beneficial applications and therapeutic doses are clinically used for 
PDT (specifically for dermatological lesions), fluorescent diagnosis and fluorescence-
guided surgery [40,41]. Many studies have conducted which have addressed the 
relationship between ABCG2 and ALA/PpIX under various experimental conditions 
and using different models. 
 
Barron et al. investigated the accumulation of exogenous ALA-produced PpIX and 
PDT in correlation with ABCG2 in multiple cell lines [42]. The different cell lines were 
found to exhibit cell-specific differences in the retention of endogenous PpIX when 
co-treated with Ko143. Cell lines were found to have increased intracellular PpIX 
levels in the presence of Ko143. Protein expression analysis found higher 
expression of ABCG2 in cells with increased intracellular PpIX levels in the presence 
of Ko143. Low ABCG2 expression was observed in cells that were not influenced in 
the retention of PpIX in the presence of Ko143. This correlated with the efficacy of 
PpIX mediated PDT, whereby ABCG2 inhibition through Ko143 enhanced PDT 
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cytotoxicity. Bebes et al. looked at the accumulation of PpIX and PDT in relation to 
the expression of ABCG2 between differentiated and proliferating HaCaT 
keratinocyte cells [43]. Differentiated HaCaT cells (low ABCG2 protein expression) 
were able to accumulate more ALA-derived PpIX when compared to proliferating 
HaCaT cells (high ABCG2 protein expression). Ko143 was found to antagonise 
ABCG2 activity and increase PpIX accumulation which was noticeable in the high 
ABCG2 expressing proliferating cells. Additionally, Ko143 improved PDT cytotoxicity 
in combined Ko143 and ALA/PpIX-PDT treated cells. 
 
Ogino et al. investigated the effects of foetal bovine serum (FBS) in cell culturing 
medium on ABCG2 activity [44]. T24 urothelial carcinoma cells were treated with 
ALA in FBS and FBS-free cell media and intracellular levels of PpIX were found to 
be significantly higher in FBS-free media cultured cells. A time- and ALA dose- 
dependant accumulation of PpIX was observed in cells cultured in FBS-free media. 
In the presence of FBS, the amount of extracellular PpIX was higher than 
intracellular PpIX. To confirm the activity of ABCG2 in eliminating PpIX in the 
presence of FBS, cells were treated with FTC and a significant increase in 
intracellular PpIX levels was observed. Similar effects were observed with cell media 
supplemented with bovine serum albumin. This study highlights the requirement of 
serum proteins to facilitate ABCG2 activity in eliminating intracellular PpIX. Hagiya et 
al. studied ALA/PpIX-PDT in different gastric cancer cell lines and the correlation 
between sensitivity to PDT and ABCG2 expression [45]. Of the various cell lines 
investigated, NKPS and MKN45 cells were found to be the most and least resistant 
to ALA/PpIX-PDT respectively. Intracellular levels of PpIX were also found to be 
lowest and highest in these particular cell lines respectively. Genetic and protein 
expression analysis showed the expression of ABCG2 in NKPS cells which was not 
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observed MKN45 cells. To confirm the activity of ABCG2, abcg2-knockdown NKPS 
cells were generated and found to have higher intracellular accumulation of PpIX 
when treated with ALA, and increased sensitivity to ALA/PpIX-PDT when compared 
to parental cells. Similar findings were observed in FTC-treated NKPS cells. The 
study by Sun et al. investigated gefitinib as a potential ABCG2 inhibitor in ALA/PpIX 
treated glioma cell lines [46]. Gefitinib was found to significantly increase intracellular 
PpIX levels in all cell lines. Gefitinib treatment reduced ABCG2 cellular membrane 
protein expression and also reduced ABCG2 gene expression. The addition of 
Gefitinib improved cellular responses to ALA/PpIX-PDT through increased 
cytotoxicity. Teshigawara et al. investigated ABCG2 and ALA/PpIX-PDT in several 
ovarian clear-cell carcinoma cell lines [47]. The different cell lines exhibited different 
levels of sensitivity to ALA/PpIX-PDT. This correlated with PpIX accumulation and 
ABCG2 gene expression, where resistant cells had lower intracellular PpIX levels 
and high ABCG2 expression. FTC treatment improved ALA/PpIX-PDT and increased 
PpIX accumulation in resistant cells. Nakayama et al. studied PpIX accumulation and 
ALA-PDT in dormant cells within a 3D spheroidal cell model [48]. Briefly, 3D 
spheroids of PC3 prostate cancer cells were generated and the presence of dormant 
cells was confirmed (characterised by the absence of cell proliferation, no cell death, 
metabolic suppression and the ability to recover to an active status). PpIX 
accumulation was found to be higher in dormant cells resulting in increased 
sensitivity to ALA/PpIX-PDT when compared to non-dormant active cells. Protein 
expression analysis showed an increase in PEPT1 (ALA influx transporter) and 
downregulation of ABCG2 in dormant cells. To confirm the effect of dormancy on 
improving PpIX accumulation and ALA/PpIX-PDT, metabolically active cell cultures 
were treated with methotrexate or cycloheximide to induce a dormant-like status 
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through cell cycle arrest. Following ALA/PpIX-PDT, ABCG2 expression was 
downregulated, PpIX accumulation had increased and cell viability had decreased.  
 
ALA-derived PpIX fluorescence has previously been identified and shown as an 
effective method for mediating fluorescence-guided surgery in patients with 
malignant glioma [49]. However, the therapeutic efficacy of ALA/PpIX-PDT in 
gliomas is currently not well understood. Briel-Pump et al. investigated ALA/PpIX-
PDT in multiple medulloblastoma and U373 glioblastoma cell lines [50]. A dose- and 
time-dependent accumulation of PpIX was observed in all cell lines; however, overall 
accumulation of PpIX was lower in medulloblastoma cell lines as compared to U373 
cells. U373 cells were more sensitive to ALA/PpIX-PDT. ABCG2 protein expression 
was detected in all medulloblastoma cell lines with no expression found in U373 
cells. 
 
The mitochondria play a key role in the production of endogenous PpIX by facilitating 
the haem biosynthesis pathway. The PpIX-converting enzyme ferrochelatase is 
located in the inner membranes of the mitochondria [51]. Palasuberniam et al. 
looked at the uptake and intracellular distribution of PpIX and ALA/PpIX-PDT in a 
panel of breast cancer cell lines (oestrogen receptor positive (ER+), human 
epidermal growth factor receptor 2 positive (HER2+) and triple negative breast 
cancer (TNBC)) [52]. TNBC cells were found to have lower intracellular PpIX 
accumulation and localisation in mitochondria when compared to ER+ and HER2+ 
cells. The levels of intracellular PpIX also correlated with ALA/PpIX-PDT cell viability; 
TNBC cells were found to be greatly resistant to PDT. Ko143 mediated ABCG2 
inhibition reversed the effects by enhancing PpIX uptake, increasing PpIX 
mitochondrial accumulation and improving responses to PDT in TNBC cells. Ko143 
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treatment had little effect on PpIX production and ALA/PpIX-PDT in ER+ and HER2+ 
cells. 
 
2.3 Hypericin 
Hypericin is a naturally occurring compound and the main chemical constituent in the 
St. John’s wort flowering plant (Hypericum perforatum) [53,54]. Low doses of 
hypericin have been used for the treatment of mild to moderate depression and 
seasonal affective disorder [53,55]. Hypericin has also been evaluated for its anti-
microbial, anti-cancer, fluorescent and photodynamic properties [56,57]. As a 
photosensitiser, hypericin exhibits bright fluorescence, potent ROS generation and 
minimal toxicity in the dark [53,55,56,58]. Hypericin’s pre-clinical success as an 
emerging photosensitiser for PDT has transitioned its investigation into a current on-
going phase III multicenter clinical trial (clinicaltrials.gov: NCT02448381)[59]. 
 
Jendželovský et al. first reported the interaction between hypericin and ABCG2 in 
HT29 cells [60]. An increase in ABCG2 expression was observed in cells treated with 
hypericin. Pre-treating cells with the ABCG2 inhibitor FTC affected its function and 
improved intracellular hypericin accumulation. Proadifen was also found to suppress 
ABCG2 activity in a similar fashion. Inhibition and suppression of ABCG2 activity 
subsequently enhanced hypericin-PDT induced oxidative stress and apoptosis. A 
follow up study by Šemeláková et al. evaluated the impact of non-activated hypericin 
and hypericin-PDT on the expression and activity of ABCG2 in HT29 cells [61]. In the 
presence of Ko143, the uptake of hypericin was found to be increased due to the 
inhibited activity of ABCG2. The incubation of cells with hypericin alone resulted in 
increased ABCG2 gene and protein expression. Following light irradiation and 
hypericin-PDT, the expression of ABCG2 had substantially reduced. The study 
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demonstrated an increase in ABCG2 expression following incubation with hypericin. 
A reduction in ABCG2 expression is only observed during hypericin-PDT. Therefore, 
the incubation period is essential to find a balance between optimal intracellular 
levels of hypericin and loss of hypericin via ABCG2. Recently, Jendželovský et al. 
further confirmed the strong affinity of ABCG2 for hypericin in the acute 
promyelocytic leukaemia cell line HL60 [62]. ABCG2-overexpressing HL60 cells 
were generated and found to have a substantially increased ability to eliminate 
hypericin when compared to the parental cell line. ABCG2-overexpressing cells were 
significantly more resistant to hypericin-PDT and no apoptotic activity was observed 
following treatment. Ko143 reversed the effects of ABCG2 overexpression in cells 
leading to an increased accumulation of hypericin and induction of apoptosis, as 
characterised by increased annexin V staining and uptake of propidium iodide. 
 
Khot et al. investigated the differences in responses to hypericin-PDT between 2D 
monolayer and 3D spheroidal models of HT29 and HCT116 colorectal cancer cell 
lines [63]. The authors found 3D spheroidal models of both cell lines to be 
significantly more resistant to Hypericin-PDT when compared to their respective 2D 
cell cultures. Protein expression analysis showed higher ABCG2 expression in 3D 
spheroidal models and co-treatment with Ko143 was found to moderately improve 
sensitivity in 3D spheroidal models of both cell lines to Hypericin-PDT. 5-
lipoxygenase (5-LOX) is responsible for the production of lipid signalling molecules 
known as eicosanoids and leukotrienes from arachidonic acid [64]. 5-LOX plays a 
role in mediating pathological inflammation and its upregulation and metabolic 
activity has been associated with tumourigenesis in different types of cancers [65]. 
Kuchárová et al. evaluated the interplay between the 5-LOX pathway and ABCG2 
and their effect on hypericin-PDT [66]. Synergistic reduction in cell viability was 
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observed in HT29 and MCF7 cells treated with hypericin-PDT and the 5-LOX 
pathway inhibitor MK-886. Increased intracellular accumulation of hypericin was 
found in cells co-treated with hypericin and MK-886, as compared to hypericin-only 
treated cells. Incubating cells with hypericin was reported to induce an increase in 
ABCG2 protein expression; however, MK-886 was reported to reduce ABCG2 
protein expression even in the presence of hypericin. This study highlights a possible 
influencing mechanism whereby inhibiting the 5-LOX pathway can hinder ABCG2 
activity and expression. 
 
Biteghe et al. investigated the expression of ABCG2 in melanoma cells co-treated 
with dacarbazine and hypericin-PDT [67]. An increase in ABCG2 expression was 
observed in cells treated with dacarbazine alone. Of the two melanoma cell lines 
evaluated, UCT Mel-1 pigmented cells showed a reduction in ABCG2 expression 
following combined treatment (hypericin and dacarbazine) or hypericin alone. A375 
unpigmented cells showed an increase in ABCG2 expression in the presence of 
hypericin. Hypericin was found to localise to the perinuclear region and hypericin-
PDT was found to enhance the cytotoxicity of dacarbazine. No significant difference 
in reduction in cell viability was observed between combined treated and hypericin-
PDT alone treated cell cultures. Combined treatment was also found to abrogate the 
self-renewal capacity of cell cultures. In this study, ABCG2 was not found to 
influence hypericin-PDT, especially in A375 unpigmented cells where an increase in 
ABCG2 expression did not result in increased resistance. 
 
2.4 Porfimer Sodium (Photofrin) 
Clinical PDT was first approved in Canada in 1993 to treat bladder cancers and 
Photofrin was the first clinically approved photosensitiser [1]. Photofrin is a first 
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generation photosensitiser and is still being used for PDT to treat lung, bladder and 
cervical cancer, and other forms of solid cancers. Due to the popularity of Photofrin 
as an agent for PDT, it is commercially available in Canada, Japan, USA and many 
European countries [68]. 
 
During PDT, light is required to activate the photosensitiser and subsequently 
generate ROS. Sonodynamic therapy (SDT) involves the use of low intensity 
ultrasound, to activate the photosensitiser and generate ROS in the presence of 
molecular oxygen [69]. Xu et al. studied the impact of Photofrin-mediated SDT with 
respect to ABCG2 in CD133+ glioma stem cells (GSC) and CD133- U251 glioma 
cells [70]. The high expression of ABCG2 has previously been identified as a 
mechanism of chemoresistance and a biomarker of GSC [71]. The uptake and 
intracellular retention of Photofrin was found to be significantly higher in U251 cells 
as compared to GSC. This resulted in higher resistance to Photofrin-SDT, reduced 
apoptosis and reduced ROS generation in GSC. ABCG2 expression was found to be 
significantly higher (around 6-fold) in GSC when compared to U251 cells. 
 
2.5 Chlorin e6 
Since the identification of haematoporphyrin derivatives in the mid-20th century as 
dynamic photosensitisers for mediating PDT, a large proportion of research in PDT 
has been occupied by the identification of new porphyrin photosensitisers. 
Alternative classes and types of photosensitisers have emerged as promising 
candidates, including chlorins and bacteriochlorins [72]. Chlorin e6 (Ce6) is an 
example of an ideal photosensitiser due to its high efficiency in singlet 
oxygen generation and activation by near-infrared wavelengths, which is suitable for 
penetration into deep tissues [73–77]. 
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As described above, ABCG2 is recognised as a possible biomarker of GSC. Abdel 
Gaber et al. investigated whether the inhibition of ABCG2 could improve Ce6-PDT in 
glioma cell lines [78]. The authors found rapid elimination of Ce6 from ABCG2-
overexpressing cells in the presence of FBS in the cell culturing media. In 
comparison, intracellular uptake and retention of Ce6 was higher in the absence of 
FBS. Ko143 was found to reduce the rate at which Ce6 was eliminated via ABCG2 
and improved cytotoxic responses to Ce6-PDT. The authors found an increase in 
ABCG2 protein expression in 3D spheroidal models of U87 cells when compared to 
2D monolayer cell cultures. 3D spheroids were also found to have reduced Ce6 
accumulation and were significantly more resistant to Ce6-PDT. 
 
2.6 Benzoporphyrin Derivative 
The photosensitiser Benzoporphyrin Derivative (BpD) has been the subject of many 
previous PDT investigations, gaining FDA approval in 2000 for clinical applications 
[79]. Huang et al. found a liposomal formulation of BpD to be an efficient mediator of 
PDT in MIA PaCa-2 pancreatic cancer cells [80]. Following a sub-lethal dose of PDT, 
ABCG2 protein expression decreased by up to 70% within 6 hours and was 
sustained for up to 24 hours. This reduction in ABCG2 was found to improve the 
uptake and retention of irinotecan in cells. 
 
2.7 Other photosensitisers 
2.7.1 PPa, MPPa, Ce6, ALA/PpIX, HpIX, mTHPP and mTHPC 
Robey et al. conducted one of the earliest studies investigating the relationship 
between the intracellular accumulation of various photosensitisers, ABCG2 
expression and PDT [22]. The authors found intracellular levels of PPa, MPPa, Ce6 
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and PpIX (generated from exogenous ALA) to be significantly lower in ABCG2-
overexpressing bronchoalveolar carcinoma cells when compared to the parental cell 
line. FTC attenuated the efflux activity of ABCG2 by increasing the intracellular 
retention of these photosensitisers. Unlike the aforementioned photosensitisers, 
intracellular accumulation of Haematoporphyrin IX (HpIX), meso-tetra(3-
hydroxyphenyl) porphyrin (mTHPP) and meso-tetra(3-hydroxyphenyl) chlorin 
(mTHPC) remained unchanged between the ABCG2-overexpressing and parental 
cells. In addition, FTC did not influence the intracellular levels of HpIX, mTHPP or 
mTHPC. Intracellular levels of the different photosensitisers in ABCG2-
overexpressing cells correlated with sensitivity to PDT. Resistance to treatment was 
observed in PPa, MPPa, Ce6 and ALA/PpIX treated cells but not in mTHPC treated 
cells. This study successfully showed differences in the affinity of different chemically 
structured photosensitisers as substrates for ABCG2 efflux activity. These 
differences critically influence intracellular retention of the photosensitisers and 
sensitivity to PDT. 
 
2.7.2 HPPa, Galactose-conjugated HPPa, ALA/PpIX and BpD 
Liu et al. investigated different photosensitisers in ABCG2-expressing (ABCG2+) and 
non-expressing (ABCG2-) cell lines [81]. Endogenous PpIX (generated from 
exogenous ALA), BpD and HPPa were shown to be substrates of ABCG2 as they 
were found to be eliminated from ABCG2+ but not from ABCG2- cells. ABCG2 
inhibition through FTC or imatinib mesylate improved the intracellular retention of 
photosensitisers and improved PDT cytotoxicity in ABCG2+ cells in vitro and murine 
RIF1 fibrosarcoma (ABCG2+) tumour xenografts in vivo. The authors attempted to 
improve the pharmacokinetics of HPPa through a chemical structural modification. 
The conjugation of galactose to HPPa significantly improved intracellular retention of 
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the photosensitiser and PDT when compared to HPPa alone in RIF1 cells. The 
addition of imatinib mesylate did not influence the effects of the HPPa galactose 
conjugate, suggesting that this modification can bypass ABCG2 transport activity. 
 
2.7.3 Photofrin and NPe6 
Usuda et al. investigated the retention of Photofrin and mono-L-aspartyl chlorin e6 
(NPe6) and PDT in abcg2-transfected A431 epidermoid carcinoma cells [82]. 
Intracellular accumulation of Photofrin was found to be substantially lower in ABCG2-
overexpressing cells when compared to the parental cell line. No difference in 
intracellular NPe6 levels was found between the two cell types suggesting that 
Photofrin is an ABCG2 substrate and NPe6 is not. Cell survival following PDT 
correlated with these findings where resistance to treatment was observed in 
Photofrin-PDT treated ABCG2-overexpressing cells. FTC reversed the effects of 
ABCG2 and improved sensitivity to Photofrin-PDT. No difference in sensitivity to 
NPe6-PDT was found between ABCG2-overexpressing and parental cells and the 
addition of FTC to NPe6-PDT did not influence sensitivity. In addition to investigating 
the in vitro differences in PDT efficacy between Photofrin and NPe6 between abcg2-
transfected and parental cells, the authors evaluated the correlation between ABCG2 
expression and responses to Photofrin and NPe6-PDT in centrally located early lung 
cancer patients. ABCG2 expression in patient tumours were scored via 
immunohistochemical staining analysis as ‘moderate expression’ [BCRP(1+)] or 
‘high expression’ [BCRP(2+)]. A complete response rate of 73.6% (42/57) was 
observed in patients treated with Photofrin-PDT. 66.7% (18/27) of those scored as 
BCRP(2+) showed complete response. In comparison, a complete response rate of 
91.6% (22/24) was seen in NPe6-PDT treated patients with 100% (18/18) scored as 
BCRP(2+) showing complete response [82,83]. 
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3 ABCG2 mediated reduction of ROS toxicity via NFκB 
The Nuclear Factor kappa-B (NFκB) protein complex is comprised of transcriptional 
factors that collectively play a central role in regulating cellular responses during 
inflammation, cell growth and survival [84]. During PDT, NFκB has been implicated 
in aiding PDT by provoking an immune response to treatment and mediating 
oxidative stress [85]. This involves the regulation of inflammatory cytokines IL-1, IL-2 
and IL-6, and activation of T-cells and macrophage inflammatory protein-1 [86,87]. 
ABCG2 has previously been shown to play a protective role against oxidative stress 
by impeding the production of ROS. This is potentially achieved by hindering the 
NFκB signalling pathway and inhibiting ROS-induced secretion of pro-inflammatory 
cytokines [88,89]. Aside from PDT applications, ABCG2 has been found to play a 
protective role in reducing oxidative stress in corneal epithelium progenitor cells [90]. 
Inhibiting ABCG2 activity resulted in increased generation of ROS. Similarly, ABCG2 
protects cardiomyocytes against oxidative stress–induced hypertrophy, by increasing 
and stabilising intracellular levels of the anti-oxidant molecule, glutathione [91]. From 
the above, it can be postulated that ABCG2 does not directly eliminate ROS, but 
rather remove ROS-generating molecules and through activating anti-oxidant 
signalling pathways. This function of ABCG2 in the context of PDT is not well 
understood and requires further exploration. 
 
4 Overcoming ABCG2 mediated resistance to PDT 
4.1 Molecular Inhibition of ABCG2 
Targeting ABCG2 and reversing the transporter activity has been studied extensively 
in an effort to improve the therapeutic index of chemotherapeutics.  
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The fungal toxin FTC was the one of the first compounds to be identified as a 
specific and potent ABCG2 inhibitor. However, FTC was found to induce strong 
neurotoxicity in vivo, preventing further investigation or potential clinical translation 
[92]. Ko143 was designed as a less toxic synthetic analogue of FTC and has been 
used extensively in ABCG2-related studies, especially PDT (Table 1). Clinically 
approved small-molecule receptor tyrosine multikinase inhibitors such as sorafenib, 
gefitinib and imatinib have also shown success in inhibiting ABCG2 [20]. In a clinical 
setting, the administration of an ABCG2 inhibitor in adjunct to PDT is an attractive 
method to improve the outcome of treatment. ABCG2 inhibitors maybe given to 
patients between the administration of photosensitisers and photo-illumination, or 
simultaneously with photosensitisers [81]. Robey et al. have recently reviewed the 
challenges of clinically exploiting ABCG2 and raised a few important considerations 
[93]. ABCG2 plays a vital role in normal physiological functions such as the transport 
of metabolites in the gastrointestinal tract, across the blood-brain barrier and in the 
kidneys. In addition to the impairment of these normal functions, the increased 
uptake of photosensitisers in normal tissues via ABCG2 inhibition could result in 
phototoxicity. A large proportion of studies investigating the inhibition of ABCG2 to 
improve PDT have been restricted to in vitro investigation. Further in vivo studies 
with more effectual clinical translation need to be conducted to successfully show 
that intervening ABCG2 activity will improve response to PDT in patients. 
 
4.2 Modifying and repackaging photosensitisers 
4.2.1 Structurally modifying photosensitisers 
 A limitation of pharmacological compounds for cancer therapeutic applications is the 
molecular mechanisms of resistance which can impair and limit the efficacy of 
treatment. In recent years, much effort and emphasis has been placed on identifying 
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ways to overcome resistance. One concept is the modification and reformulation of 
existing therapeutics. This includes the conjugation of compounds onto therapeutics, 
the incorporation of targeting moieties and repackaging therapeutics in drug-
delivering liposomal vesicles and nanomedicines [94–97]. Zheng et al. report on the 
conjugation of carbohydrate moieties to HPPa [98]. The conjugation of galactose to 
HPPa (HPPa-Gal) was found to improve intracellular uptake and retention in 
ABCG2-expressing RIF1 cells when compared to free HPPa. This resulted in more 
efficient PDT and increased cell death in HPPa-Gal treated cells. No difference in 
photosensitiser uptake was observed in HPPa-Gal and free HPPa treated Colon26 
cells (negligible ABCG2 expression). In vivo analysis showed elevated light dose-
dependent activity of HPPa-Gal in comparison to free HPPH in RIF1 tumour 
xenograft bearing mice. A larger proportion of mice in the HPPa-Gal-PDT treated 
group were cured of their tumours. Toxicity analysis showed little to no skin 
phototoxicity in HPPa-Gal treated mice. HPPa treated mice experienced strong 
erythema, possibly due to a large amount of HPPa being eliminated and not retained 
within xenografts. Morgan et al. conducted a similar study investigating structural 
modifications to HPPa and affinity for ABCG2 using carbohydrate conjugations [99]. 
The authors found HPPa-Gal was retained to a higher degree in ABCG2-expressing 
HEK293 cells when compared to free HPPa. Imatinib mesylate was found to further 
enhance intracellular retention of HPPa-Gal. PDT cytotoxicity was evaluated in 4T1 
breast cancer cells in vitro and in vivo, and HPPa-Gal-PDT treated cells were found 
to be the most sensitive to treatment. A side population of high ABCG2 expressing 
cells were identified in an overall low ABCG2 expressing tumour xenograft. These 
cells possess stem-like properties and could potentially initiate tumour regrowth 
following PDT. Although resistant to HPPa-PDT, these stem-like cells were also 
found to be sensitive to HPPa-Gal-PDT. 
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Rapozzi et al. designed and evaluated a photosensitiser conjugate consisting of PPa 
conjugated to an androgen receptor ligand through a small pegylated linker [100]. 
Overexpression of the androgen receptor in prostate cancer makes it a promising 
candidate for developing targeting therapeutics and a biomarker for drug 
development [101]. Intracellular retention of the PPa conjugate was found to be 
higher in PC3 prostate cancer cells than the free PPa. The ABCG2 inhibitor 
reserpine was found to increase free intracellular PPa levels but did not influence the 
accumulation of the androgen receptor-binding PPa conjugate. This suggests that 
the conjugate is not a substrate for ABCG2 efflux activity. Following light irradiation, 
higher phototoxicity was observed in PPa conjugate treated cells when compared to 
free PPa treated cells. These studies show that through structurally modifying 
photosensitisers, their affinity for ABCG2 efflux activity is reduced, whilst their 
photodynamic properties are retained. 
 
4.2.2 Photosensitiser nanoparticle reformulation 
Indocyanine green (ICG) is a well-documented photosensitive agent with multiple 
clinical applications including fluorescent cholangiography, angiography and the 
detection of sentinel lymph nodes [102,103]. ICG can also be used for PDT and 
generates ROS by near-infrared irradiation. Li et al. investigated PDT using ICG 
covalently conjugated to gold nanospheres [104]. SKOV3 and CT26 cells were 
treated with ICG-conjugates or free ICG and, following light irradiation, higher toxicity 
was observed in ICG-conjugate treated cell cultures. An increase in Nrf2 expression 
was detected following PDT using both free and ICG-conjugates as a response to 
the production of ROS. As highlighted earlier, Nrf2 can induce the upregulation of 
ABCG2. Following PDT, an increase in ABCG2 was found in free ICG treated cells 
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and decreased following subsequent rounds of light treatment as free ICG was 
rapidly eliminated from cells. ABCG2 expression remained stable in cells treated with 
ICG conjugated nanospheres. Intracellular ICG fluorescence was also seen to be 
higher, suggesting that the nanosystem provided a way for ICG to escape ABCG2-
mediated elimination. Roh et al. investigated the efficacy between Ce6 and Ce6-
encapsulated polymeric nanoparticles functionalised with polyethylene glycol and 
polyethylenimine in AsPC-1 (moderate ABCG2 expression), MIA PaCa-2 (negligible 
ABCG2 expression) and abcg2-transfected MIA PaCa-2 (high ABCG2 expression) 
pancreatic cancer cell lines [105]. Intracellular retention of free Ce6 correlated with 
ABCG2 expression where low, moderate and high Ce6 levels were found in abcg2-
transfected MIA PaCa-2, AsPC-1 and MIA PaCa-2 cells respectively. The opposite 
was observed in cells treated with Ce6-nanoparticles, with highest Ce6 levels in 
abcg2-transfected cells, suggesting that the nanoparticle reformulation can 
overcome ABCG2 activity. PDT induced cytotoxicity correlated with intracellular Ce6 
levels. Nanoparticle reformulation of Ce6 significantly enhanced phototoxicity, 
improved ROS generation and improved sensitivity to treatment, especially in abcg2-
transfected cells. Ko143 was found to further enhance phototoxicity in Ce6-
nanoparticle treated cells. In vivo findings also showed Ce6-nanoparticle-PDT to be 
the most effective in reducing tumour size in AsPC-1 tumour xenograft bearing mice. 
Recently, Baglo et al. developed nanoliposomal formulations of phospholipids 
conjugated to BpD and investigated PDT in differential ABCG2-expressing cell 
cultures [106]. ABCG2 overexpressing MCF7 cells were found to rapidly eliminate 
BpD when compared to parental cells. FTC improved the retention of BpD, 
confirming ABCG2 activity. In comparison, the nanoliposomal formulation of BpD 
improved the uptake of BpD and no difference was observed in the presence of FTC. 
This further translated into PDT efficacy, with nanoliposomal-BpD-PDT treated 
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ABCG2 overexpressing MCF7 cells experiencing the highest phototoxicity. 
Nanoparticle reformulations are an effective way of masking photosensitisers, 
bypassing ABCG2 efflux activity, and improving intracellular retention and overall 
PDT activity. 
 
4.3 Hyperthermia and ABCG2 expression in PDT 
A recent study by Kurokawa et al. investigated the influence of hyperthermia in 
improving PDT through downregulating the expression of ABCG2 [107]. 
Hyperthermia (1 hour at 42°C) was found to improve the uptake and retention of 
haematoporphyrin dihydrochloride (HpD) in cancer-like mutant variants of the rat 
gastric epithelial cell line RGM-1. Hyperthermia-mediated increased intracellular 
accumulation of HpD resulted in increased HpD fluorescence and generation of 
mitochondrial ROS. Hyperthermia and PDT synergistically reduced cell viability when 
compared to either method alone. The increase in ROS via hyperthermia also led to 
an upregulation of the heme carrier protein-1 (HCP-1) and downregulation of ABCG2 
protein expression, which was reversed by the ROS scavenger N-acetyl-L-cysteine. 
Hyperthermia can improve PDT by downregulating ABCG2 and upregulating HCP-1 
by mitochondrial ROS. This study is a single example and further validation is 
required in different cancer models to prove the credibility of hyperthermia as an 
effective method for improving PDT efficiency. This method would be ideally suited 
to combined thermal ablation (tissue temperature should be maintained between 41–
44°C) and PDT in the clinical setting. 
 
4.4 Non-ABCG2 substrate photosensitisers 
The relationship between ABCG2 and its affinity for photosensitisers has 
predominantly been studied through experimental analysis. Studies have shown that 
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popular photosensitisers such as PPa, ALA/PpIX, Ce6 and hypericin are subject to 
ABCG2 activity; however, non-ABCG2 substrate photosensitisers such as mTHPC 
and NPe6 have shown to be, in part, unaffected by the presence of ABCG2 
[22,33,82,83]. The studies by Robey et al. and Usuda et al. identified mTHPC and 
NPe6 as potential photosensitisers to overcome ABCG2-mediated resistance to 
PDT. Although this requires further validation, the clinical implication of this finding 
means stratifying patients according to ABCG2 expression levels and using non-
ABCG2 substrate photosensitisers for PDT in high ABCG2 expressing cancers to 
improve the likelihood of eradicating tumours through bypassing ABCG2 resistance. 
Berg and colleagues are recognised as pioneering the concept of photochemical 
internalisation (PCI). Briefly, a therapeutic agent is packaged with a photosensitiser 
into endocytic vesicles. Upon light irradiation, ROS generated by the photosensitiser 
ruptures the membrane of the vesicle and releases the therapeutic agent at the site 
of interest [108]. The photosensitisers di-sulfonated meso-tetraphenylporphine 
(TPPS2a), di-sulfonated mesotetraphenylchlorin (TPCS2a) and di-sulfonated 
aluminiumphtalocyanine (AlPcS2a) are commonly used in PCI and have been 
reported as non-ABCG2 substrate photosensitisers [109]. All three photosensitisers 
were found to be retained in ABCG2-expressing MA11 breast cancer cells. Co-
incubation with FTC did not influence intracellular photosensitiser levels and cells 
were found to be sensitive to PDT, irrespective of FTC mediated ABCG2 inhibition. 
In contrast, low levels of photosensitiser was found in PPa treated MA11 cells and 
FTC was required to improve PPa retention and sensitivity to PDT. The same group 
did a follow-up study to examine the resensitisation of PDT-resistant cells using the 
non-ABCG2 substrate photosensitiser TPCS2a [110]. MA11 cells were subjected to 
repeated cycles of PPa-PDT and surviving cells were selected to generate a PPa-
PDT resistant cell line. Protein expression confirmed increased ABCG2 expression 
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in resistant cells when compared to parental cells. PPa-PDT resistant cells were 
subjected to TPCS2a-PDT and were found to respond to treatment. 
 
Patient selection is key to identify those that will effectively respond to PDT. ABCG2 
expression has been identified as a marker of cancer stem-like cells and an 
influencing factor of resistance to PDT [111]. Administering large doses of ABCG2-
substrate photosensitisers and prolonging treatment times might overcome ABCG2-
mediated efflux in tumours to some degree. This approach would also greatly reduce 
the therapeutic index and risk unacceptable adverse photosensitivity [81]. In these 
cases, co-treatment with an ABCG2 inhibitor or use of a non-ABCG2 substrate 
photosensitiser could potentially be successful approaches to enhancing clinical 
PDT. 
 
5 The protective role of ABCG2 against phototoxicity and protoporphyria 
Under normal physiology, ABCG2 plays a protective role in maintaining intracellular 
levels of haem. Jonker et al. found that improper ABCG2 function resulted in excess 
accumulation of photosensitive compounds leading to cutaneous protoporphyria [24]. 
Under stressful and harmful conditions such as hypoxia, ABCG2 regulates toxic 
levels of cellular porphyrins and haem, aiding cell survival [112–114]. Endogenous 
PpIX levels are continuously regulated by ABCG2, to prevent a build-up of the 
photosensitiser that can lead to phototoxicity [115]. Kobuchi et al. found ABCG2 
distributed in the mitochondrial fraction to play a role in regulating endogenous PpIX 
levels [116]. Mitochondrial ABCG2 can transport PpIX from the mitochondria to the 
cytosol and ABCG2 localised to the plasma membrane can eliminate PpIX from 
cells. Blocking ABCG2 activity increases intracellular accumulation of PpIX. 
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ABCG2 is therefore vital for regulating cellular homeostasis of porphyrins, to prevent 
phototoxicity [117]. This is confirmed by Tamura et al. that found genetic 
polymorphisms resulting in ABCG2 inactivity or the inhibition of wild-type ABCG2, 
resulted in increased intracellular accumulation of porphyrins and acute 
photosensitivity in non-cancerous cells [118]. From a clinical standpoint, adverse 
cutaneous phototoxicity has previously been observed in patients treated with the 
ABCG2 inhibitor, imatinib mesylate [119]. To achieve maximum therapeutic benefit, it 
is important to find a balance between PDT and adverse protoporphyria. The normal 
physiological activity of ABCG2 is vital to prevent phototoxicity, yet it can hinder the 
retention of photosensitisers and affect PDT. 
 
6 Conclusion 
This review elucidates the impact of the transmembrane protein ABCG2 on the 
pharmacokinetics of photosensitisers and the efficacy of PDT. The role of ABCG2 in 
conferring chemoresistance has been well-documented and extends to PDT. Many 
studies have demonstrated different methods for overcoming ABCG2-mediated 
resistance to PDT. This includes co-treatment with ABCG2 inhibitors, using non-
ABCG2 substrate photosensitisers and the modification of ABCG2 substrate 
photosensitisers to reduce binding affinity. The role of ABCG2 in protecting against 
phototoxicity is necessary in normal tissues, yet can hinder PDT in cancers. The 
studies described here are primarily pre-clinical evaluations. Careful consideration 
and further validation of the most effective method for downplaying ABCG2 in 
cancers for PDT is required prior to clinical applications.   
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FIGURE 1 
 
 
Figure 1. Graphical representation of the photosensitiser efflux activity of 
ABCG2 
The dimerising transmembrane ATP-dependant ABCG2 efflux pump eliminates the 
intracellular accumulation of photosensitisers (PS) out of cells. ABCG2 inhibitors can 
directly bind and antagonise the activity of ABCG2 which improves the intracellular 
retention of photosensitisers for PDT. 
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Table 1. An overview of the studies included in this review  
Photosensitisers 
Experimental 
models 
ABCG2 
inhibitors 
Outcomes of study Reference 
PPa 
abcg2 
knockdown 
mice in vivo 
and fibroblast 
cell line in vitro 
Ko143 
abcg2 knockdown 
mice experienced 
phototoxicity. 
ABCG2 
overexpression 
reduced PS 
accumulation. 
Ko143 reversed 
effects of ABCG2. 
Jonker 2002 
[24] 
Colorectal 
cancer cell 
lines in vitro 
and tumour 
xenografts in 
vivo 
Ko143 
PS uptake, ROS 
generation and PDT 
correlated with 
ABCG2 expression. 
Ko143 reversed 
effects of ABCG2.  
Kim 2015 [25] 
Ovarian cancer 
cell line in vitro 
Ko143 
PI3K/Akt inhibition 
and cMET 
repression lead to 
ABCG2 
suppression, 
increased PS 
uptake, increased 
ROS generation 
and improved PDT. 
Ko143 reversed 
effects of ABCG2. 
Jung 2015 [30] 
Various 
carcinoma cell 
lines in vitro 
Ko143 
Nrf2 knockdown 
increased PS 
uptake, increased 
ROS generation 
and improved PDT. 
Nrf2 knockdown 
lead to ABCG2 
suppression. Ko143 
did not affect 
ABCG2 activity in 
Nrf2 knockdown 
cells. 
Choi 2014 [36] 
Prostate 
cancer cell line 
in vitro 
Reserpine 
Androgen receptor 
ligand-conjugated 
PS improved PS 
retention and PDT. 
Rapozzi 2015 
[97] 
 
41 
 
Reserpine improved 
retention of free PS 
MPPa 
Osteosarcoma 
cell lines in 
vitro 
- 
PDT resistant cells 
(selected through 
repeated treatment) 
showed increased 
ABCG2 expression, 
reduced PS uptake 
and reduced ROS 
generation. PDT 
resistant cells were 
capable of invasion, 
migration and 
formed colonies 
after treatment. 
Tao 2017 [32] 
Glioma cell 
lines in vitro 
FTC 
Varying levels of 
sensitivity to PDT 
between different 
cell lines. This 
correlated with PS 
accumulation and 
ABCG2 expression. 
FTC inhibited 
ABCG2 activity. 
Pan 2017 [31] 
Ovarian cancer 
cell lines in 
vitro 
- 
PDT induced an 
increase in Nrf2 
expression. Nrf2 
knockdown 
increased ROS 
generation and 
improved PDT. 
Tian 2017 [37] 
HPPa 
Patient-derived 
primary lung 
carcinoma, 
healthy lung 
epithelial and 
stromal cells in 
vitro 
Imatinib 
Mesylate 
Low PS 
accumulation in 
high ABCG2 
expressing cells. 
Imatinib Mesylate 
reversed effects of 
ABCG2. 
Tracy 2011 [33] 
Fibrosarcoma 
and colon 
carcinoma cell 
lines in vitro 
and in vivo 
- 
Conjugation of 
galactose improved 
PS uptake and PDT 
in vitro and in vivo. 
Galactose 
conjugation 
improved toxicity of 
PS. 
Zheng 2009 
[95] 
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Various cell 
lines (cancer 
and non-
cancer) in vitro 
and in vivo 
Imatinib 
Mesylate 
Conjugation of 
galactose improved 
PS uptake in vitro 
and PDT in vitro 
and in vivo. Imatinib 
Mesylate enhanced 
PS uptake and 
retention 
Morgan 2010 
[96] 
ALA/PpIX 
Various cell 
lines (cancer 
and non-
cancer) in vitro 
Ko143 
PS uptake and PDT 
correlated with 
ABCG2 expression. 
Ko143 reversed 
effects of ABCG2.  
Barron 2013 
[42] 
Keratinocyte 
cell line in vitro 
Ko143 
PS uptake and PDT 
correlated with 
ABCG2 expression. 
Ko143 reversed 
effects of ABCG2.  
Bebes 2011 
[43] 
Urothelial 
carcinoma cell 
line in vitro 
FTC 
FBS in cell media 
facilitated ABCG2 
mediated 
elimination of PS. 
FTC reversed 
effects of ABCG2. 
Ogino 2011 [44] 
Gastric cancer 
cell lines in 
vitro 
FTC 
Varying levels of 
sensitivity to PDT 
between different 
cell lines. This 
correlated with PS 
accumulation and 
ABCG2 expression. 
abcg2-knockdown 
increased PS 
uptake and 
improved PDT. FTC 
reversed effects of 
ABCG2. 
Hagiya 2012 
[45] 
Glioma cell 
lines in vitro 
Gefitnib 
Gefitinib increased 
PS uptake, reduced 
ABCG2 expression 
and improved PDT. 
Sun 2013 [46] 
Ovarian clear-
cell carcinoma 
cell lines in 
vitro 
FTC 
Varying levels of 
sensitivity to PDT 
between different 
cell lines. This 
correlated with PS 
accumulation and 
Teshigawara 
2018 [47] 
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ABCG2 expression. 
FTC reversed 
effects of ABCG2. 
Prostate 
cancer cell line 
in vitro 
- 
PS accumulation 
and PDT was 
enhanced in 
dormant cells. 
PEPT1 was 
upregulated and 
ABCG2 was 
downregulated in 
dormant cells. 
Nakayama 
2016 [48] 
Brain cancer 
cell lines in 
vitro 
- 
Glioblastoma cells 
had higher PS 
uptake, lower 
ABCG2 expression 
and were more 
sensitive to PDT 
than 
medulloblastoma 
cell lines. 
Briel-Pump 
2018 [50] 
Breast cancer 
and normal cell 
lines in vitro 
Ko143 
TNBC cells had 
lower PS 
accumulation and 
mitochondrial 
localisation and 
higher resistance to 
PDT than ER+ and 
HER2+ cells. Ko143 
reversed effects of 
ABCG2.  
Palasuberniam 
2015 [52] 
Hypericin 
Colorectal 
cancer cell line 
in vitro 
Proadifen* 
and FTC 
The uptake of PS 
increased ABCG2 
expression. 
Proadifen and FTC 
reduced ABCG2 
activity resulting in 
increased PS 
uptake, enhanced 
oxidative stress and 
improved PDT. 
Jendželovský 
2009 [60] 
Colorectal 
cancer cell line 
in vitro 
Ko143 
Ko143 treatment 
increased PS 
uptake. Incubation 
with PS increased 
ABCG2 expression. 
ABCG2 expression 
Šemeláková 
2016 [61] 
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reduced following 
PDT. 
Acute 
promyelocytic 
leukemia cell 
line in vitro 
Ko143 
ABCG2-
overexpressing 
cells had reduced 
PS uptake, 
increased PDT 
resistance and no 
apoptotic activity 
following PDT. 
Ko143 reversed 
effects of ABCG2. 
Jendželovský 
2019 [62] 
Colorectal 
cancer cell 
lines in vitro 
Ko143 
3D spheroids were 
more resistant to 
PDT than 2D cell 
cultures. ABCG2 
protein expression 
was higher in 3D 
spheroids.  
Khot 2018 [63] 
Various cancer 
cell lines in 
vitro 
- 
MK-886 (5-LOX 
inhibitor) can 
synergistically 
increase PS uptake, 
reduce ABCG2 
expression and 
enhance PDT. 
Kuchárová 
2015 [66] 
Melanoma cell 
lines in vitro 
- 
Uncorrelated 
ABCG2 expression 
was found between 
different cell lines 
incubated with PS. 
PS enhanced 
Dacarbazine 
cytotoxicity and 
abrogate self-
renewal capacity of 
cells. ABCG2 
expression did not 
influence PDT. 
Biteghe 2017 
[67] 
Photofrin 
Glioma cell 
lines in vitro 
 
High ABCG2 
expressing glioma 
stem cells had 
lower PS uptake, 
higher SDT 
resistance, reduced 
apoptosis and 
reduced ROS 
generation as 
Xu 2012 [70] 
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compared to low 
ABCG2 expressing 
glioma cells. 
Ce6 
Glioma cell 
lines in vitro 
Ko143 
FBS in cell media 
facilitated ABCG2 
mediated 
elimination of PS. 
Ko143 reversed 
effects of ABCG2. 
3D spheroids were 
more resistant to 
PDT than 2D cell 
cultures. ABCG2 
protein expression 
and PS 
accumulation was 
higher and lower in 
3D spheroids 
respectively. 
Abdel Gaber 
2018 [78] 
Pancreatic 
cancer cell 
lines in vitro 
and in vivo 
Ko143 
Nanoparticle 
reformulation of PS 
improved PS 
uptake, improved 
ROS generation 
and improved PDT. 
Ko143 further 
enhanced 
nanoparticle PDT. 
Roh 2017 [102] 
BpD 
Pancreatic 
cancer cell line 
in vitro 
- 
Sub-lethal PDT 
reduced ABCG2 
expression and 
improved the 
uptake of irinotecan 
Huang 2016 
[80] 
Breast cancer 
cell lines in 
vitro 
FTC 
Nanoliposomal 
repackaging of PS 
improved cellular 
retention and PDT. 
FTC reversed 
effects of ABCG2. 
Baglo 2019 
[103] 
PPa, MPPa, 
Ce6, ALA/PpIX, 
HpIX, mTHPP 
and mTHPC 
Various cell 
lines (cancer 
and non-
cancer) in vitro 
FTC 
Varying degrees of 
intracellular 
retention of different 
PS was observed in 
ABCG2-
overexpressing 
cells. FTC 
modulated ABCG2 
activity. Intracellular 
Robey 2005 
[22] 
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concentrations of 
PS correlated with 
sensitivity to PDT 
HPPa, 
Galactose-
conjugated 
HPPa, 
ALA/PpIX and 
BpD 
Various cell 
lines (cancer 
and non-
cancer) in vitro 
and murine 
fibrosarcoma 
tumour 
xenografts in 
vivo 
FTC and 
Imatinib 
Mesylate 
PS retention was 
low in ABCG2-
positive cells. 
ABCG2 inhibitors 
improved PS 
retention and PDT 
in vitro and in vivo. 
Galactose 
conjugation 
improved PS 
retention and PDT. 
Liu 2007 [81] 
Photofrin and 
NPe6 
Epidermoid 
carcinoma cell 
line in vitro and 
patient tumour 
tissue for IHC 
staining 
FTC 
Photofrin retention 
was low and PDT 
resistance was 
seen in ABCG2-
overexpressing 
cells. FTC reversed 
effects of ABCG2. 
ABCG2 expression 
did not influence 
NPe6 retention and 
PDT. NPe6-PDT 
was more efficient 
in high ABCG2 
expressing patient 
tumours. 
Usuda 2010 
[82] 
Indocyanine 
green 
Various cancer 
cell lines in 
vitro 
- 
PS conjugated to 
gold nanospheres 
improved cellular 
retention and PDT. 
Li 2017 [101] 
HpD 
Rat gastric 
epithelial cell 
line in vitro 
- 
Hyperthermia 
improved PS 
uptake, increased 
ROS generation 
and improved PDT. 
Kurokawa 2019 
[104] 
TPPS2a, 
TPCS2a, AlPcS2a 
and PPa 
Breast cancer 
cell line in vitro 
FTC 
All PS except PPa 
were found to be 
non-ABCG2 
substrates 
Selbo 2012 
[106] 
TPCS2a and 
PPa 
Breast cancer 
cell line in vitro 
- 
High ABCG2 
expressing cells 
that are resistant to 
PPa (ABCG2 
substrate)-PDT 
Olsen 2017 
[107] 
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were sensitive to 
TPCS2a (non-
ABCG2 substrate)-
PDT 
Abbreviations: PDT: Photodynamic Therapy; PS: Photosensitiser; NPe6: Mono-L-aspartyl 
chlorin e6; FTC: Fumitremorgin C; ROS: Reactive Oxygen Species; ABCG2: ATP-binding 
cassette superfamily G member 2; FBS: Foetal Bovine Serum; PEPT1: Peptide 
transporter 1; TNBC: Triple Negative Breast Cancer; ER+: Oestrogen Receptor Positive; 
HER2+: Human Epidermal Growth Factor Receptor 2 Positive; 5-LOX: 5-lipoxygenase; 
SDT: Sonodynamic Therapy; PPa: Pheophorbide-a; MPPa: Pyropheophorbide-a methyl 
ester; HPPa: 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; ALA/PpIX: Aminolevulinic 
acid/Protoporphyrin IX; Ce6: Chlorin e6; BpD: Benzoporphyrin Derivative; HpIX: 
Haematoporphyrin IX; mTHPP: meso-tetra(3-hydroxyphenyl) porphyrin; mTHPC: meso-
tetra(3-hydroxyphenyl) chlorin; IHC: Immunohistochemistry; HpD: haematoporphyrin 
dihydrochloride; TPPS2a: Di-sulfonated meso-tetraphenylporphine; TPCS2a: Di-sulfonated 
meso-tetraphenylchlorin; AlPcS2a: Di-sulfonated aluminiumphtalocyanine; 
*Proadifen did not directly inhibit ABCG2 but was found to suppress ABCG2 activity. 
 
